Close

Seattle Genetics (SGEN) Updates on Multiple Presentations Made at ISHL

Go back to Seattle Genetics (SGEN) Updates on Multiple Presentations Made at ISHL

Leerink Partners Remains Bullish Ahead of Seattle Genetics's (SGEN) 3Q Report

October 21, 2016 9:05 AM EDT

Leerink Partners reiterated an Outperform rating and $62.00 price target on Seattle Genetics (NASDAQ: SGEN) ahead of the company's 3Q release. Leerink is expecting the company to report relatively in-line results. Expectations are for total revenue of $101M compared to consensus of $101.7M. Estimates for diluted loss per share of... More